Literature DB >> 15775995

Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells.

Shaoyi Li1, Tsutomu Tokuyama, Junkoh Yamamoto, Masayo Koide, Naoki Yokota, Hiroki Namba.   

Abstract

Since neural stem cells (NSCs) have the ability to migrate toward a tumor mass, genetically engineered NSCs were used for the treatment of gliomas. We first evaluated the "bystander effect" between NSCs transduced with the herpes simplex virus-thymidine kinase (HSVtk) gene (NSCtk) and C6 rat glioma cells under both in vitro and in vivo conditions. A potent bystander effect was observed in co-culture experiments of NSCtk and C6 cells. In the intracranial co-implantation experiments in athymic nude mice and Sprague-Dawley rats, the animals co-implanted with NSCtk and C6 cells and treated with ganciclovir (GCV) showed no intracranial tumors and survived more than 100 days, while those treated with physiological saline (PS) died of tumor progression. We next injected NSCtk cells into the pre-existing C6 tumor in rats and treated them with GCV or PS. The tumor volume was serially measured by magnetic resonance imaging. The tumor disappeared in six out of nine rats in the NSCtk/GCV group, while all the rats treated with PS died of tumor progression by day 21. The results indicate the feasibility of a novel gene therapy strategy for gliomas through a bystander effect generated by intratumoral injection of NSCtk cells and systemic GCV administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15775995     DOI: 10.1038/sj.cgt.7700826

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  35 in total

Review 1.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

Review 2.  Neural stem cell therapy for cancer.

Authors:  Juli Rodriguez Bagó; Kevin T Sheets; Shawn D Hingtgen
Journal:  Methods       Date:  2015-08-24       Impact factor: 3.608

Review 3.  Special cells, special considerations: the challenges of bringing embryonic stem cells from the laboratory to the clinic.

Authors:  R C Addis; J W M Bulte; J D Gearhart
Journal:  Clin Pharmacol Ther       Date:  2008-03       Impact factor: 6.875

Review 4.  Novel treatment strategies for malignant gliomas using neural stem cells.

Authors:  Michael C Oh; Daniel A Lim
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Radiolabeling strategies for radionuclide imaging of stem cells.

Authors:  Esther Wolfs; Catherine M Verfaillie; Koen Van Laere; Christophe M Deroose
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

6.  Neural stem cell-based gene therapy for brain tumors.

Authors:  Seung U Kim
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

7.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

Review 8.  Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas.

Authors:  Prakash Rath; Huidong Shi; Joel A Maruniak; N Scott Litofsky; Bernard L Maria; Mark D Kirk
Journal:  Curr Stem Cell Res Ther       Date:  2009-01       Impact factor: 3.828

9.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012

Review 10.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.